BC Extra | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BC Week In Review | May 2, 2019
Company News

Forge, Basilea to develop antibiotics against unexploited targets

Forge and Basilea Pharmaceutica International Ltd. partnered to discover, develop and commercialize antibiotics against two undisclosed metalloenzyme targets the partners say have been difficult to drug. Basilea will pay an undisclosed upfront payment to access...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Week In Review | Jan 18, 2019
Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate...
BC Week In Review | Apr 20, 2018
Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor (FGF) receptor...
BC Extra | Apr 17, 2018
Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong...
BC Extra | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
BC Extra | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...
BC Extra | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

Infectious disease company Melinta Therapeutics Inc. (New Haven, Conn.) hired Dan Wechsler as president and CEO and John Bluth as EVP of investor relations and corporate communications. Wechsler was operating partner at Welsh, Carson, Anderson...
BC Week In Review | Sep 29, 2017
Company News

Basilea grants China Resources Holdings rights to Zevtera in China

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong...
Items per page:
1 - 10 of 342
BC Extra | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BC Week In Review | May 2, 2019
Company News

Forge, Basilea to develop antibiotics against unexploited targets

Forge and Basilea Pharmaceutica International Ltd. partnered to discover, develop and commercialize antibiotics against two undisclosed metalloenzyme targets the partners say have been difficult to drug. Basilea will pay an undisclosed upfront payment to access...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Week In Review | Jan 18, 2019
Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate...
BC Week In Review | Apr 20, 2018
Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor (FGF) receptor...
BC Extra | Apr 17, 2018
Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong...
BC Extra | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
BC Extra | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...
BC Extra | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

Infectious disease company Melinta Therapeutics Inc. (New Haven, Conn.) hired Dan Wechsler as president and CEO and John Bluth as EVP of investor relations and corporate communications. Wechsler was operating partner at Welsh, Carson, Anderson...
BC Week In Review | Sep 29, 2017
Company News

Basilea grants China Resources Holdings rights to Zevtera in China

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong...
Items per page:
1 - 10 of 342